Ovarian Cancer Drugs Market by Drug Class (Angiogenesis inhibitors, Poly (ADP Ribose) Polymerase Inhibitors, Programmed Cell Death Protein 1 Ligand 1 Inhibitors), Pipeline Analysis by Target and Development Stage and Forecast 2017-2021

Ovarian Cancer Drugs Market by Drug Class (Angiogenesis inhibitors, Poly (ADP Ribose) Polymerase Inhibitors, Programmed Cell Death Protein 1 Ligand 1 Inhibitors), Pipeline Analysis by Target and Development Stage and Forecast 2017-2021

Ovarian cancer is a cancer that forms in or on an ovary.  It results in abnormal cells that have the ability to invade or spread to other parts of the body. In 2015, it was present in 1.2 million women and resulted in 161,100 deaths worldwide. The risk of ovarian cancer increases in women who have ovulated more over their lifetime. A family history of ovarian cancer is a risk factor for ovarian cancer. People with strong genetic risk for ovarian cancer may consider the surgical removal of their ovaries as a preventative measure. Other risk factors include hormone therapy after menopause, fertility medication, and obesity. A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery. Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of the disease, the subtype of cancer present, and other medical conditions. Chemotherapy in ovarian cancer typically consists of platins, a group of platinum-based drugs, combined with non-platins. Common therapies can include paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, and gemcitabine. The vascular endothelial growth factor (VEGF) inhibitor, bevacizumab (Avastin; Roche/ Genentech), is approved (excluding the United States) as a first-line treatment in combination with standard chemotherapy. In Europe and the United States, bevacizumab is also approved for recurrent ovarian cancer.

The global ovarian cancer drugs market segmentation is based on drug class (angiogenesis inhibitors, poly (ADP ribose) polymerase inhibitors, programmed cell death protein 1 ligand 1 inhibitors), and pipeline analysis by target and development stage.

The global ovarian cancer drugs market report provides market size (Revenue US$ Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global ovarian cancer drugs market research report is further segmented by geography into North America (U.S.), Europe (U.K., Germany, France, Italy, Spain), Asia Pacific (Japan), and Rest of the World. The global ovarian cancer drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global ovarian cancer drugs market and profiled in this report include AbbVie, AstraZeneca (Acerta Pharma), Boehringer Ingelheim GmbH, Five Prime Therapeutics, Gradalis, Incyte Corporation, MacroGenics, Mateon Therapeutics, Merck KGaA, Novartis, Novogen, Inc., Oasmia Pharmaceuticals, Pfizer, Inc., PharmaMar (Chugai), and Roche (Genentech).

  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Ovarian Cancer Drugs Market

1. Drug Class
1.1. Angiogenesis inhibitors
1.2. Poly (ADP Ribose) Polymerase (PARP) Inhibitors
1.3. Programmed Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors

2. Pipeline Analysis by Target and Development Stage

3. Geography (Region, Country)
3.1. North America (U.S.)
3.2. Europe (U.K., Germany, France, Italy, Spain)
3.3. Asia Pacific (Japan)
3.4. Rest of the World

4. Company Profiles
4.1. AbbVie
4.2. AstraZeneca (Acerta Pharma)
4.3. Boehringer Ingelheim GmbH
4.4. Five Prime Therapeutics
4.5. Gradalis
4.6. Incyte Corporation
4.7. MacroGenics
4.8. Mateon Therapeutics
4.9. Merck KGaA
4.10. Novartis
4.11. Oasmia Pharmaceuticals
4.12. Pfizer, Inc.
4.13. PharmaMar (Chugai)
4.14. Roche (Genentech)

Request market specific full ToC and sample pages for this report

Full Name*


Phone Number* [Please add country code]